Aro Biotherapeutics

Philadelphia, PA · Founded 2018 · Privately Held (backing)

Developer of a protein drug platform designed to unlock the potential of genetic medicines. Aro Biotherapeutics is based in Philadelphia, PA and was founded in 2018. It was valued at $182 million at its later-stage round in Nov 2023, the last priced event on record. It has raised $132 million across 4 recorded rounds; the latest was a $24 million early-stage round in Dec 2022.

PMV mark · valuation
$181.5M
Oct 2026
Priced at
its later-stage round
Nov 2023
Total raised
$131.8M
Last round
Early Stage VC
Dec 2022

Who backs Aro Biotherapeutics?

10 investors
InvestorType
Johnson & Johnson Innovation - JLABSOther
Johnson & Johnson JJDCVenture capital
Ridgeback CapitalVenture capital
Avego Management—
BVF Partners—
Blue Owl Credit Income—
Cowen Healthcare Investments—
HealthCap—
Ionis Pharmaceuticals—
Northpond Ventures—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Aro Biotherapeutics investors

10 investors are on record for Aro Biotherapeutics, including Johnson & Johnson Innovation - JLABS, Johnson & Johnson JJDC, Ridgeback Capital and Avego Management. The early-stage round in Dec 2022 drew 12 investors.

Free account
More of Aro Biotherapeutics with a free account
  • ·Watch Aro Biotherapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 10 firms already write checks for companies like Aro Biotherapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View